Table I.

Anti-cancer activity of nitroxoline in vitro.

Cell line	Origin of cell line	Inhibition rate at 80 µM, %	IC50, µM	Inhibition rate at 10 µM, %
HUVEC	Human umbilical vein endothelial cells	97.1±1.2	7.06±1.64	66.1±7.5
T24	Bladder transitional cell carcinoma	99.4±0.5	1.68±0.09c	94.0±2.4b
5637	Bladder grade II carcinoma	98.0±1.9	2.45±0.23b	87.9±1.9b
KCC853	Clear cell renal cell carcinoma	96.1±2.3	2.96±0.89a	86.0±7.8a
HepG2	Hepatocellular carcinoma	95.3±2.2	5.75±1.04	57.4±0.6
SGC-7901	Gastric carcinoma	96.1±2.9	7.18±0.19	43.6±2.5b
A549	Lung adenocarcinoma	75.1±1.6c	11.43±2.07	53.6±6.7
MCF7	Breast adenocarcinoma	74.1±0.9c	20.58±4.83c	51.1± 2.1a
J82	Bladder transitional cell carcinoma	57.8±1.2c	20.83±5.47b	46.8±7.4a
LoVo	Colorectal carcinoma	45.0±1.1c	5.99±0.56	33.6±1.4c
HELF	Human embryonic lung fibroblasts	39.8±1.2c	13.26±2.61	2.9±0.8c

Data are presented as mean ± standard deviation.

^aP<0.05

^bP<0.01

^cP<0.001 vs. HUVEC cells (one-way analysis of variance with Tukey's post-hoc test). IC₅₀, half maximal inhibitory concentration.